1. Home
  2. ALT vs FRGE Comparison

ALT vs FRGE Comparison

Compare ALT & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • FRGE
  • Stock Information
  • Founded
  • ALT 1997
  • FRGE 2014
  • Country
  • ALT United States
  • FRGE United States
  • Employees
  • ALT N/A
  • FRGE N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • FRGE Computer Software: Prepackaged Software
  • Sector
  • ALT Health Care
  • FRGE Technology
  • Exchange
  • ALT Nasdaq
  • FRGE Nasdaq
  • Market Cap
  • ALT 327.4M
  • FRGE 262.8M
  • IPO Year
  • ALT N/A
  • FRGE N/A
  • Fundamental
  • Price
  • ALT $3.87
  • FRGE $17.88
  • Analyst Decision
  • ALT Strong Buy
  • FRGE Buy
  • Analyst Count
  • ALT 6
  • FRGE 5
  • Target Price
  • ALT $17.40
  • FRGE $35.50
  • AVG Volume (30 Days)
  • ALT 2.5M
  • FRGE 91.5K
  • Earning Date
  • ALT 11-11-2025
  • FRGE 11-05-2025
  • Dividend Yield
  • ALT N/A
  • FRGE N/A
  • EPS Growth
  • ALT N/A
  • FRGE N/A
  • EPS
  • ALT N/A
  • FRGE N/A
  • Revenue
  • ALT $20,000.00
  • FRGE $90,840,000.00
  • Revenue This Year
  • ALT N/A
  • FRGE $32.56
  • Revenue Next Year
  • ALT $761,880.20
  • FRGE $21.75
  • P/E Ratio
  • ALT N/A
  • FRGE N/A
  • Revenue Growth
  • ALT N/A
  • FRGE 14.78
  • 52 Week Low
  • ALT $2.90
  • FRGE $6.60
  • 52 Week High
  • ALT $11.16
  • FRGE $24.90
  • Technical
  • Relative Strength Index (RSI)
  • ALT 55.49
  • FRGE 48.37
  • Support Level
  • ALT $3.56
  • FRGE $15.58
  • Resistance Level
  • ALT $3.72
  • FRGE $17.93
  • Average True Range (ATR)
  • ALT 0.18
  • FRGE 1.07
  • MACD
  • ALT 0.03
  • FRGE -0.12
  • Stochastic Oscillator
  • ALT 51.15
  • FRGE 62.87

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About FRGE Forge Global Holdings Inc.

Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.

Share on Social Networks: